Adiso Therapeutics has emerged from stealth mode with a pipeline of therapies including live biotherapeutic (LBP) strains focused on tackling inflammatory diseases.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
In recent years, it has become clear that RNA molecules are an emerging as a class of therapeutics of relevance to multiple diseases, most recently including COVID-19 vaccines.
